Chief Business Officer, Lilly New Ventures at Eli Lilly and Company
Katie Hewitt is Chief Business Officer for Lilly New Ventures at Eli Lilly and Company where she is responsible for venture strategy and transactions with a focus on leveraging Lilly’s deep scientific expertise and drug development capabilities to supplement Lilly’s pipeline. Since joining Lilly in 2001, she has held many leadership roles on US and global teams across finance, business development, strategy, and commercialization. This includes leading cross-functional deal teams for important programs in COVID-19 which led to the first-in-class launch of Lilly’s monoclonal antibody, bamlanivimab, in 2020. She is passionate about working at the intersection of science and business and enjoys mentoring early-in-career professionals in the art of negotiation and deal-making. Hewitt earned her bachelor’s degree in economics and sociology from DePauw University and holds certifications from Harvard Business School. She is also a practicing black belt in taekwondo and a certified paramotor pilot. She lives in Indianapolis, Indiana, with her two children.